X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.reuters.com/markets/deals/amgen-set-buy-biotech-firm-horizon-26-bln-valuation-bloomberg-news-2022-12-12/?rpc=401&
https://www.fiercepharma.com/pharma/horizons-krystexxa-gets-new-combo-indication-methotrexate-breathes-new-life-drug
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125293
https://www.businesswire.com/news/home/20211101005290/en/New-Data-Being-Presented-at-American-College-of-Rheumatology-Convergence-2021-Highlight-Horizon%E2%80%99s-Commitment-to-Improving-Outcomes-for-People-Living-with-Uncontrolled-Gout
https://www.biospace.com/article/releases/nls-pharmaceutics-ceo-issues-letter-to-shareholders/
https://www.clinicaltrialsarena.com/news/horizon-krystexxa-methotrexate-primary-endpoint/
https://www.renalandurologynews.com/home/conference-highlights/national-kidney-foundation-annual-meeting/nkf-2021-spring-meeting/pegloticase-used-successfully-for-uncontrolled-gout-in-dialysis-patients/#:~:text=Pegloticase%20is%20successfully%20being%20used,Foundation%202021%20Spring%20Clinical%20Meetings.
https://www.businesswire.com/news/home/20210325005128/en/First-Patient-Enrolls-in-FORWARD-Trial-to-Evaluate-Monthly-Dosing-of-KRYSTEXXA%C2%AE-pegloticase-injection-and-Methotrexate-to-Treat-Uncontrolled-Gout
https://ir.horizontherapeutics.com/news-releases/news-release-details/higher-response-rates-recipe-randomized-controlled-trial
https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-initiates-clinical-trial-assess-shorter
https://www.biospace.com/article/releases/new-data-offers-insights-on-treatment-with-krystexxa-pegloticase-injection-among-kidney-transplant-patients-for-the-management-of-uncontrolled-gout/
https://www.biospace.com/article/releases/target-enrollment-reached-in-mirror-randomized-controlled-trial-evaluating-krystexxa-pegloticase-injection-co-prescribed-with-methotrexate-as-an-immunomodulator-to-enhance-response-rates-for-people-living-with-uncontrolled-gout/
https://www.biospace.com/article/releases/data-presented-on-krystexxa-pegloticase-injection-co-prescribed-with-an-immunomodulator-adds-to-growing-body-of-evidence-for-this-treatment-approach-/
https://finance.yahoo.com/news/data-multiple-immunomodulation-approaches-krystexxa-120000032.html
https://www.fiercepharma.com/marketing/horizon-bulks-up-salesforce-ahead-750m-inflammatory-eye-drug-launch
http://ir.horizon-pharma.com/news-releases/news-release-details/horizon-pharma-plc-reports-record-quarterly-net-sales-orphan-and
Market Place
Share 
